Skip to main content
. Author manuscript; available in PMC: 2016 May 15.
Published in final edited form as: Cancer Res. 2015 Mar 13;75(10):1972–1982. doi: 10.1158/0008-5472.CAN-14-2761

Figure 2. Heterozygous loss of WNT5A is common in cancer.

Figure 2

A. WNT5A expression in TCGA Illumina HiSeq level 3 breast-cancer dataset by sample type (P = 0.0154, n= 112 for normal tissues and n= 1040 for invasive cancer). B. Kaplan-Meier curve to show the overall survival between the highest WNT5A-expressing samples (n=126) and the lowest WNT5A-expressing samples (n=125) among the Agilent G4502A level 3 microarray TCGA BRCA dataset. ***: P = 0.0003. C. Copy number variations (CNV) from different TCGA datasets were analyzed using UCSC cancer genome browser and plotted as percentages of specimens with any loss of WNT5A alleles. D. WNT5A expression in BRCA TCGA Illumina HiSeq level 3 by PAM50 molecular subtype. P values comparing Normal samples (n=60) to Luminal A (n=211, P = 0.0142), Luminal B (n=128, P < 0.0001), HER2 (n=58, P = 0.0389), and basal-like breast cancer (BLBC, n=78, P < 0.0001). E. Kaplan-Meier curve to show the overall survival between WNT5A bialleles (WT, n=519) and either homozygous or heterozygous deletion of WNT5A alleles (Δhomo/het, n=249) among Illumina HiSeq RNAseq level 3 BRCA data. **: P = 0.0098.